We would like to update you on the change of the CEEGOG residence. The proposal for the new place of residence was approved by all participants at the CEEGOG meeting in December 2016. Starting June, 2017, the Association resides in the city of Prague, Na Folimance 2155/15, Praha 2 – Vinohrady.
Finally, there is an upcoming meeting with the industry in October 2017, where Ph1/Ph2 representatives will present their trial proposals. In relation to that, prof. Vergote spoke about the existing ENGOT rules on the cooperation with the industry
On March 3 - 4, 2017, a meeting of representatives of the twenty national trial groups was held in Spanish Valencia. CEEGOG was represented by its Chairman Prof. David Cibula and the administrative manager Mrs. Ivana Nohová.
Have previously been diagnosed and treated for ovarian cancer, peritoneal cancer, and/or fallopian tube cancer and their disease has come back.
Have an inherited BRCA mutation. In case of an unknown BRCA status, patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy. Note: The BRCA test is covered by the sponsor.
We would like to express our thanks for your participation in the CEEGOG meeting held in Prague on December 9, 2016. It is our pleasure to invite the 9 new centers for cooperation. Currently CEEGOG is composed of 39 centres from 8 countries – the Czech Republic, Slovakia, Poland, Slovenia, Ukraine, Hungary, Belarus, Georgia.
We would like to invite CEEGOG members and friends to the CEEGOG meeting, which is going to be held at the General University Hospital in Prague on Friday, December 9, 2016, from 9:30 am to 16:00 pm. Both CEEGOG members and CEEGOG friends are cordially invited to attend the meeting.
On October 6-7, 2016, a meeting of representatives of national trial groups was held at Scandic Stortoget Hotel in Malmö. CEEGOG was represented by its chairman Prof. David Cibula and the administrative manager Mrs. Ivana Nohová.
The Engot Admin meeting was focused on ENGOT documentation, risk based monitoring and budgeting a trial, monitoring network, on EU regulation and the GCP amendment.
The ENGOT Administrative meeting was followed by the ENGOT assembly meeting. The main topic involved trial activities and the status of collaboration. Group participation in ENGOT studies was also evaluated. Prof. David Cibula delivered a presentation on the ABRAX proposal of CEEGOG. It was decided that this could be an ENGOT tial. All groups showed interest in ABRAX. Other topics for discussion were as follows: privileged partnership application of EVA group (Brazil), new PGOG application, update of publication rules and reports from the ESGO council and working groups.
More information may be provided by the CEEGOG office on request.
The Gynaecological Cancer Academy (GCA), which is run by ENGOT, sets itself the goal of nurturing and developing the next generation of leaders in gynaecological oncology in order to ensure continuity and the transfer of knowledge and experience among members of the clinical trial community.
The 8th GCA workshop took place in Baveno on September 30, 2016. CEEGOG was represented by two physicians, namely Dr. Jaroslav Klát (University Hospital in Ostrava) and Dr. Roman Kocián (General University Hospital in Prague).
The main topic of the workshop was Non-ovarian cancer. The most important presentations of the training module are webcasted and available on ESGO eAcademy.
We would like to inform you that our Association has endorsed the CEEGOG membership application of the Maribor center. We are pleased that CEEGOG has been expanding and currently includes centers from 4 countries - the Czech Republic, Slovakia, Poland and newly Slovenia.
Page 1 of 2